Invasive Meningococcal Disease

Discontinue Use of Ciprofloxacin for Invasive Meningococcal Disease Post-Exposure Prophylaxis

Health care providers should discontinue the use of ciprofloxacin as post-exposure prophylaxis (PEP) for close contacts of patients with invasive meningococcal disease in New York due to antimicrobial resistance. Rifampin or ceftriaxone remain first-line options for meningococcal disease PEP. Azithromycin may also be used as an alternative.

Treatment recommendations for suspected or confirmed invasive meningococcal disease have not changed. Start appropriate antibiotics (e.g., a third-generation cephalosporin) as soon as invasive meningococcal disease is suspected; do not wait for diagnostic test results.

NYC Health Department Health Advisory #23: Discontinue Use of Ciprofloxacin for Invasive Meningococcal Disease Post-Exposure Prophylaxis (PDF, August 14, 2024)